ImmunityBio's Anktiva sales rise 53% to $48.7m after wider US approval

ImmunityBio reported net product revenue of $48.7 million for Anktiva in the third quarter of 2026, up 53% on the same quarter a year earlier. The figure comes from the company's own announcement on 9 November, and the drug's revenue trajectory is now tied to a broader US label.

The FDA cleared a supplemental application on 14 October that extends Anktiva, given alongside BCG, to adults with BCG-unresponsive non-muscle invasive bladder cancer whose tumours are papillary-only. The company did not set out in the material available how many patients this adds or how it expects the change to affect sales.

Outside the US, ImmunityBio said Israel has approved the product, which it describes as the 35th approval globally. It also said the first patients in Europe have been treated. The information available does not say through which regulatory route, or in which countries, that treatment is taking place.

The company is also looking at earlier disease. It said the QUILT-2.005 cohort of BCG-naïve patients reached its primary endpoint and that it plans to file a supplemental application for that group in the fourth quarter of 2026. No detailed data were provided, and the filing date is the company's intention, not a regulatory commitment.